Anti‐Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form
Journal of Medical Virology · 2026-06 · 98 (6)
DOI: 10.1002/jmv.71000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 04.06.2026. Verfasst von Ying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Pek…. Hauptthemen laut MEDLINE: Antiviral Agents, RNA Replication, Virus Replication, Zika Virus. Die Arbeit nennt 20 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS), National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
The outbreak of the Zika virus (ZIKV) poses a significant threat to global public health. Currently, there are no approved antiviral drugs specifically targeting ZIKV. This highlights the urgent need for the development of effective therapeutic agents. Azvudine (FNC), an antiviral drug approved in China for treating HIV/AIDS and later granted conditional approval for COVID‐19, is a promising candidate for drug repurposing. In this study, we found FNC inhibited ZIKV replication in a cell‐based replicon system we established. This inhibition was confirmed by significant reductions in ZIKV RNA and NS5 protein levels, as demonstrated by RT‐qPCR, Western blot, and immunofluorescence analyses. Moreover, FNC effectively inhibited the ZIKV (SMGC‐1) strain with an EC 50 of 6.62 μM, comparable to that of the known ZIKV inhibitor NITD008. LC‐MS/MS analysis revealed efficient intracellular uptake of FNC and its conversion to the active triphosphate metabolite FNC‐TP. We further showed that FNC‐TP, but not FNC, acted as a nucleoside analog to directly inhibit the RNA‐dependent RNA polymerase (RdRp), preventing RNA chain elongation with an IC 50 of 4.93 μM. These findings provided the first evidence of FNC's anti‐ZIKV activity, revealing that its convention to FNC‐TP is the key mechanism for inhibiting viral RNA synthesis and highlighting its potential as a promising anti‐ZIKV agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Ning Sheng
Förderung
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Chen, Y., Lan, Y., Zhao, A., Zhang, Y., Han, Y., Sheng, N., Lin, Y., Zhang, J., & Jiang, J. (2026). Anti‐Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71000
Vancouver
Chen Y, Lan Y, Zhao A, Zhang Y, Han Y, Sheng N, et al. Anti‐Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71000
BibTeX
@article{Chen2026,
author = {Chen, Ying and Lan, Yi and Zhao, Anzhuo and Zhang, Yu and Han, Yanxing and Sheng, Ning and Lin, Yuan and Zhang, Jinlan and Jiang, Jiandong},
title = {Anti‐Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {6},
doi = {10.1002/jmv.71000}
}
EUVIMED